No information is available on the clinical use of lapatinib during breastfeeding. Because lapatinib is more than 99% bound to plasma proteins, the amount in milk is likely to be low. However, its half-life is about 24 hours and it might accumulate in the infant. It is also given in combination with capecitabine, which may increase the risk to the infant. The manufacturer recommends that breastfeeding be discontinued during lapatinib therapy and for 1 week after the last dose.
关于拉帕替尼在哺乳期的临床应用尚无可用信息。由于拉帕替尼与血浆蛋白的结合率超过99%，其在乳汁中的含量可能较低。然而，它的半衰期约为24小时，可能会在婴儿体内蓄积。它还与卡培他滨联合使用，这可能会增加对婴儿的风险。制造商建议在拉帕替尼治疗期间及最后一剂后1周内停止母乳喂养。
